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Abstract
Objective: To determine the effects that mutation of the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene and deletion of the glutathione S-transferase (GST) genes mu-1 (GSTM1) and theta-1 (GSTT1) have 
on the clinical course of cystic fibrosis (CF) in patients residing in the southeastern region of Brazil. Methods: The 
study sample consisted of all consecutive CF patients treated at the Hospital de Clínicas School of Medical 
Sciences of the State University at Campinas between March of 2002 and March of 2005. We included 66 CF 
patients. Genomic DNA was analyzed by polymerase chain reaction and restriction endonuclease digestion for the 
identification of the genotypes. Results: The ΔF508 mutation of the CFTR gene was found in 44 patients (66.7%). 
The null genotypes GSTM1, GSTT1 and GSTM1/GSTT1 were found in 40.9%, 15.2%, and 3.0% of the patients, 
respectively. The ΔF508 CFTR mutation was more common in patients diagnosed with CF before 2.5 years of age 
than in those diagnosed later (75.5% vs. 41.2%; p = 0.008). The frequency of the ΔF508 CFTR mutation, as well 
as of the GSTM1 and GSTT1 genotypes, was not found to be associated with gender, ethnicity, pulmonary disease 
status, or pancreatic disease status. Conclusions: When the patients were stratified by clinical and epidemiological 
features, the frequencies of the GSTM1 and GSTT1 null genotypes were similar, suggesting that the inherited 
absence of these enzymatic pathways does not alter the course of CF. However, the high frequency of the ΔF508 
CFTR mutation found in younger children suggests that it influences the age at diagnosis of CF in this region of 
Brazil.
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Resumo
Objetivo: Determinar os efeitos que a mutação do gene cystic fibrosis transmembrane conductance regulator 
(CFTR) e da deleção dos genes glutationa S-transferase (GST) mu-1 (GSTM1) e teta-1 (GSTT1) têm na evolução 
clínica da fibrose cística (FC) em pacientes da região sudeste do Brasil. Métodos: Entre março de 2002 e março 
de 2005, incluímos no estudo todos os pacientes consecutivos de FC atendidos no Departamento de Pediatria do 
Hospital de Clínicas da Faculdade de Ciências Médicas da Universidade Estadual de Campinas. O DNA genômico de 
66 pacientes com FC foi analisado por reação em cadeia da polimerase e digestão com endonuclease de restrição 
para a identificação dos genótipos. Resultados: A mutação ΔF508 do gene CFTR foi identificada em 44 (66.7%) 
pacientes. As deleções dos genes GSTM1, GSTT1 e da combinação nula GSTM1/GSTT1 foram identificadas em 
40,9%, 15,2% e 3,0% dos pacientes, respectivamente. A mutação ΔF508 do gene CFTR foi mais comum em 
pacientes diagnosticados com FC antes dos 2,5 anos de idade que naqueles diagnosticados mais tarde (75,5% 
vs. 41,2%; p = 0,008). Foram observadas frequências similares da mutação ΔF508 do gene CFTR e dos genótipos 
GSTM1 e GSTT1 nos pacientes, independentemente do sexo, etnia ou status da doença pulmonar ou pancreática. 
Conclusões: Quando os pacientes foram estratificados por aspectos clínicos e epidemiológicos, as frequências dos 
genótipos GSTM1 e GSTT1 nulos foram semelhantes, sugerindo que a ausência herdada dessas vias enzimáticas 
não altera o curso da FC. Em contraste, a alta frequência da mutação ΔF508 no gene CFTR encontrada em 
pacientes mais jovens sugere que essa mutação influencia a idade no momento do diagnóstico de FC nessa região 
do país.
Descritores: Fibrose cística; Regulador de condutância transmembrana em fibrose cística; Glutationa transferase.
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Methods
The study sample consisted of all consecutive 
CF patients treated in the Hospital de Clinicas of 
the State University of Campinas, located in the 
city of Campinas, Brazil, between March of 2002 
and March of 2005. The diagnosis of CF was 
based on signs and symptoms, such as failure 
to thrive, meconium ileus, vomiting, abdominal 
pain, diarrhea, steatorrhea, and recurrent 
pulmonary infections. Two tests of chloride 
concentration in sweat, with results equal to or 
greater than 60 mEq/L and performed by the 
classical pilocarpine test,(17) were required for 
confirmation of the diagnosis. We considered 
the age at diagnosis of CF, as well as the current 
severity of the pulmonary and pancreatic 
diseases, as measured by the Shwachman score.
(18) All procedures were carried out in accordance 
with the ethical principles of the institutional 
guidelines, and all patients or their relatives gave 
written informed consent.
Genomic DNA of peripheral blood was 
used for the genotyping of all CF patients. The 
ΔF508 CFTR mutation was detected directly by 
polymerase chain reaction (PCR; Figure 1a).(19) 
The G542X, G551D, R553X, R1162X, W1282X, 
and N1303K mutations of the CFTR gene were 
analyzed by restriction endonuclease digestion 
of the PCR products.(20) The genes GSTM1, 
GSTT1 and β-globin (as a reaction control) were 
amplified by multiplex-PCR (Figure 1b).(21) 
The patients were stratified by the pattern 
of CFTR gene mutation (homozygous ΔF508 
mutation, heterozygous ΔF508 mutation, 
and other or unknown CFTR mutations) 
and GSTM1 and GSTT1 gene mutations 
(present or with homozygous deletion). We 
used the chi-square test or Fisher’s exact test 
to calculate the statistical significance of 
differences in age (< 1.0 year vs. ≥ 1.0 year; 
and < 2.5 years vs. ≥ 2.5 years); gender (male 
vs. female); ethnic origin (White vs. African-
Brazilian); and lung and pancreatic exocrine 
status (excellent/good/mild vs. moderate/
severe); and GSTM1 and GSTT1 genotypes 
(present vs. null), isolated or in combination. The 
associations of genotypes and clinical variables 
were also evaluated by multivariate analysis 
using a logistic regression model. Factors with a 
p ≤ 0.05 were considered statistically significant.
Introduction
Cystic fibrosis (CF) is one of the most common 
severe autosomal recessive genetic diseases 
among populations of northern European 
descent. The major clinical manifestations of the 
disorder are chronic sinopulmonary disease and 
pancreatic exocrine insufficiency.(1)
There is considerable heterogeneity among 
individuals with CF in terms of the severity 
of the disease. Attempts to link phenotypes 
to specific CF transmembrane conductance 
regulator (CFTR) gene mutations have been 
successful, particularly for pancreatic disease 
status.(2-5) This correlation, however, has 
not completely held for pulmonary disease, 
which can vary markedly among patients 
with the same CFTR gene mutation.(6) The 
severity of pulmonary disease in CF seems to 
be influenced by other mutations located out 
of the CFTR gene locus,(7,8) such as the those 
occurring in the glutathione S-transferase 
(GST) enzymes.(9-13) Glutathione is a major local 
pulmonary antioxidant that is present in the 
epithelial lining fluid. The GST enzymes detoxify 
harmful organic hydroperoxides that are formed 
as a result of exposure to oxidant stress, such as 
those found in the lungs of patients with CF,(14) 
by conjugating them with glutathione, thereby 
potentially preventing further pulmonary 
damage. 
The genes GST mu-1 (GSTM1) and GST 
theta-1 (GSTT1) are polymorphic in humans and 
are absent or homozygous null, resulting in a 
lack of active proteins, in approximately 40% 
and 20% of normal individuals, respectively.(15) 
In CF, there is no consensus regarding the roles 
of the GSTM1 and GSTT1 null genotypes in 
the severity of lung disease(9-13) and pancreatic 
disease.(9)
Among Whites in Brazil, CF is one of the 
most common severe inherited diseases.(16) Short 
survival due to pulmonary disease has been 
described in CF patients treated at our hospital.
(16) However, the modifiers of disease severity, if 
any, are still unknown. Therefore, we considered 
it necessary to identify the CFTR mutation, as 
well as the GSTM1 and GSTT1 genotypes, in CF 
patients in Brazil, in order to determine whether 
these genetic factors influence the clinical 
course of the disease in the southeastern region 
of the country. 
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of the CFTR gene were found in heterozygosis 
in 8 (12.1%), 2 (3.0%), and 1 (1.5%) of the 
patients, respectively. The G551D, R553X, and 
W1282X mutations were not found in any of 
our patients. We found that 19 of the patients 
did not have any of the mutations studied. 
The allelic frequencies of the ΔF508, G542X, 
R1162X, and N1303K mutations of the CFTR 
gene were 0.462, 0.061, 0.015, and 0.008, 
respectively. The frequencies of the homozygous 
and heterozygous ΔF508 CFTR mutations were 
similar in patients under and over 1.0 year of 
age (34.8% and 31.8%, respectively; p = 0.18). 
However, such mutations were more common 
in patients under 2.5 years of age than in the 
older patients (75.5% vs. 41.2%; p = 0.008). 
No significant differences regarding gender, 
ethnic origin, or lung/exocrine pancreatic 
disease status were observed among the CF 
patients in relation to the distinct patterns of 
the CFTR mutation. Similar frequencies of the 
G542X, R1162X, and N1303K mutation patterns 
of the CFTR gene (data not shown), as well as 
of the GSTM1, GSTT1, and GSTM1/GSTT1 null 
genotypes, were seen in patients under and over 
1.0 year of age (data not shown). The same was 
All analyses were performed using the 
statistical package SAS System for Windows, 
version 8.1 (SAS Institute, Cary, NC, USA). 
Results
The study involved 66 patients with CF 
(Table 1). The median age of the patients at 
diagnosis was 1.0 year (range, 0.1-15.0 years). At 
the time of CF diagnosis, 27 of the patients were 
younger than 1.0 year of age, 39 were at least 
1.0 year old, 49 were under 2.5 years of age, 
and 17 were over 2.5 years of age. Males and 
females were similarly represented in the study. 
Almost all individuals were White. Moderate and 
severe forms of CF were found in 57.6% of the 
patients. The prevalences of these forms of the 
disease were similar in patients under and over 
1.0 year of age (59.2% and 56.4%, respectively; 
p = 1.00), as well as in those under and over 
2.5 years of age (61.2% and 47.1%, respectively; 
p = 0.40). 
The ΔF508 CFTR mutation was identified in 
44 of the 66 patients (66.7%). The homozygous 
and heterozygous mutations were seen in 
17 (25.8%) and in 27 (40.9%), respectively. 
The G542X, R1162X, and N1303K mutations 
Figure 1 - Polymerase chain reaction for the detection of the ΔF508 mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, as well as of the deletion of glutathione S-transferase (GST) genes mu-1 
(GSTM1) and theta-1 (GSTT1), in cystic fibrosis. In a, 12% polyacrylamide gel stained with ethidium bromide 
showing 45-bp and 48-bp fragments, corresponding to the mutant and normal alleles, respectively. Lane 1 
shows the result from an individual with the homozygous ΔF508 mutation; lanes 2, 4, and 5 show the results 
of individuals without the ΔF508 mutation, whereas lane 3 shows the result from a heterozygous individual. 
A control sample without DNA and a 10-bp DNA ladder are presented in lanes 6 and 7, respectively. In b, 2% 
agarose gel stained with ethidium bromide showing 273-bp, 480-bp, and 630-bp fragments, corresponding 
to the genes GSTM1, GSTT1, and β-globin (as a reaction control), respectively. Lane 1 also shows a 100-bp 
DNA ladder. Lanes 2 and 8 show the results from individuals with the GSTM1 and GSTT1 genes. Lanes 3 and 6 
show a combined homozygous GSTM1 and GSTT1 deletion. Lanes 4 and 5 show the results from individuals 
with homozygous deletion of GSTM1, whereas lane 7 shows the results from an individual with homozygous 
deletion of GSTT1.
a b
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ΔF508 CFTR gene mutation was the most 
common mutation found in our study, which 
corroborates other reports from the same 
region of Brazil,(16,22-25) as well as international 
reports.(26,27) Other mutations of the CFTR gene, 
such as R1162X and N1303K, were less common 
in our CF patients,(22,24,28) as has been reported 
for CF patients in other parts of the world.(27) 
The frequencies of the GSTM1 and GSTT1 null 
genotypes in the CF patients in our study were 
similar to those found in healthy individuals, 
in Brazil(29) and elsewhere.(15) Therefore, our 
sample seems to be representative of CF patients 
throughout the world.
We found a high frequency of the ΔF508 
CFTR mutation in patients diagnosed with the 
disease before 2.5 years of age in comparison 
with those diagnosed later. However, we found 
no difference in the frequencies of the gene 
mutation in patients stratified by lung/pancreatic 
disease status. Because the frequencies of the 
moderate and severe forms of CF were similar in 
the patients under and over 2.5 years of age, the 
combination of the ΔF508 CFTR gene mutation 
and the diagnosis of the disease at a younger 
age suggests that the mutation provokes more 
symptoms or makes symptoms more persistent, 
true for patients under and over 2.5 years of age 
at diagnosis, regardless of gender, ethnic origin, 
or lung/exocrine pancreatic disease status 
(Table 1). Similar frequencies of the distinct 
patterns of the CFTR mutations in combination 
with the genotypes GSTM1 null, GSTT1 null, 
and GSTM1/GSTT1 null were seen in patients 
under and over 1.0 year of age (data not shown). 
After multivariate analysis, the frequencies of 
the genotypes were also similar among patients 
stratified by age (< 2.5 and ≥ 2.5 years of 
age), gender, ethnic origin, and lung/exocrine 
pancreatic disease status (Table 2). No differences 
in age, gender, ethnic origin, or lung/exocrine 
pancreatic disease status were seen among the 
patients with the G542X, R1162X, or N1303K 
mutations in the CFTR gene combined with 
the GSTM1, GSTT1, or GSTM1/GSTT1 null 
genotypes (data not shown).
Discussion
The distribution of the patients enrolled in 
the study by age at diagnosis, gender, ethnic 
origin, and severity of lung/exocrine pancreatic 
disease status showed that our CF patients 
were similar to those in other countries.(1) The 
Table 1 - The mutations of the CFTR gene and GSTM1 and GSTT1 null genotypes in relation to the clinical 
variables in cystic fibrosis patients.





Null Null One null Both null
n (%) n (%) n (%) n (%) n (%) n (%)
Age, yearsa
< 2.5* 49 37 (75.5) 12 (24.5) 22 (44.9) 6 (12.2) 26 (53.1) 1 (2.0)
≥ 2.5* 17 7 (41.2) 10 (58.8) 5 (29.4) 4 (23.5) 7 (41.2) 1 (5.9)
Gender 66
Male 35 22 (62.9) 13 (37.1) 16 (45.7) 7 (20.0) 19 (54.3) 2 (5.7)
Female 31 22 (71.0) 9 (29.0) 11 (35.4) 3 (9.7) 14 (45.2) 0 (0.0)
Ethnic group 66
White 65 43 (66.2) 22 (33.8) 27 (41.5) 9 (13.9) 32 (49.2) 2 (3.1)
African-Brazilian 1 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0)
Lung disease statusb 66
Mildc 36 24 (66.7) 12 (33.3) 16 (44.4) 6 (16.7) 20 (55.6) 1 (2.8)
Severed 30 20 (66.7) 10 (33.3) 11 (36.7) 4 (13.3) 13 (43.3) 1 (3.3)
Exocrine pancreatic disease statusb 66
Mildc 28 18 (64.3) 10 (35.7) 12 (42.9) 5 (17.9) 15 (53.6) 1 (3.6)
Severed 38 26 (68.4) 12 (31.6) 15 (39.5) 5 (13.2) 18 (47.4) 1 (2.6)
aAge at diagnosis of the disease. bDefined using the Shwachman score. cIncluding excellent, good, and mild status. dIncluding 
moderate and severe status. *p = 0.02 for the comparison of frequencies of homozygous and heterozygous ΔF508 CFTR 
mutation in patients under and over 2.5 years of age; OR = 5.0 (95% CI: 1.5-16.7), and p = 0.008 was obtained for the 
same analysis when results were adjusted by the multivariate analysis.
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possible that our patients did not survive long 
enough to present pancreatic dysfunction.
We found no differences between the patients 
with the GSTM1 or GSTT1 genes and those 
without in terms of age, gender, ethnic origin, 
or lung/pancreatic disease status, suggesting 
that the GST enzymes do not alter the clinical 
characteristics of CF patients in our region. The 
GST multigene family of detoxifying enzymes is 
involved in protecting various tissue types from 
oxidative damage. The homozygous GSTM1 
null genotype has been associated with greater 
lung disease severity and decreased survival in 
CF patients,(9-11,13) although there are conflicting 
data.(12) In addition, we found that the inherited 
absence of the GSTM1(9) and GSTT1(11,12) enzymes 
was not associated with the severity of pancreatic 
or lung disease. Although the absence of these 
GST proteins might have altered the clinical 
function of our CF patients, their influence might 
not have been strong enough to be detected 
in our sample. Furthermore, the ΔF508 CFTR 
mutation combined with the GSTM1 or GSTT1 
null genotypes were also equally distributed 
among our CF patients, stratified by the clinical 
which might prompt the parents of patients with 
this mutation to seek medical advice sooner.
The ΔF508 mutation results in the 
production of an abnormally folded CFTR that 
is not trafficked normally to the apical cell 
membrane.(30) In fact, there is evidence that 
the gene abnormality alone does not affect the 
severity of the lung disease.(6,16,26) This seems to 
be influenced by other mutations located out 
of the CFTR locus. In addition, the association 
between the ΔF508 mutation and the severity 
of pancreatic exocrine insufficiency in CF 
patients has been consistently demonstrated.(2,5) 
Therefore, it is noteworthy that our sample size 
(n = 66) might not have been sufficient to detect 
associations between the ΔF508 mutation in the 
CFTR gene and the clinical features, and that 
the method used for determining the lung/
pancreatic disease status (the Shwachman score) 
might have been inappropriate for the purposes 
of this study. In addition, a second mild allele 
accompanying the ΔF508 mutation might have 
protected our patients against severe pancreatic 
disease, as previously described.(2,5) It is also 
Table 2 - The ΔF508 CFTR gene pattern combined with the GSTM1 and GSTT1 null genotypes in cystic fibrosis 
patients stratified by clinical variables.













n (%) n (%) n (%) n (%) n (%) n (%)
Age, yearsa
< 2.5* 16 (72.7)d 6 (27.3) 6 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
≥ 2.5* 1 (20.0) 4 (80.0) 2 (50.0) 2 (50.0) 0 (0.0) 1 (100.0)
Gender
Male 9 (56.3) 7 (43.8) 6 (85.7) 1 (14.3) 1 (50.0) 1 (50.0)
Female 8 (72.7) 3 (27.3) 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0)
Ethnic group
White 17 (63.0) 10 (37.0) 7 (87.5) 2 (12.5) 1 (50.0) 1 (50.0)
African-Brazilian 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lung disease statusb
Mildc 11 (68.8) 5 (31.3) 6 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
Severed 6 (54.5) 5 (45.5) 2 (50.0) 2 (50.0) 0 (0.0) 1 (100.0)
Exocrine pancreatic disease statusb 
Mildc 9 (75.0) 3 (25.0) 5 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
Severed 8 (53.3) 7 (46.7) 3 (60.0) 2 (40.0) 0 (0.0) 1 (100.0)
aAge at diagnosis of the disease. bDefined using the Shwachman score. cIncluding excellent, good, and mild status. 
dIncluding moderate and severe status. *p = 0.06 for the comparison of the frequencies of the GSTM1 null genotype and 
ΔF508 CFTR mutation in patients under and over 2.5 years of age; OR = 14.05 (95% CI: 0.76-260.25), and p = 0.76 was 
obtained for the same analysis when results were adjusted by the multivariate analysis.
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In conclusion, our data provide preliminary 
evidence that the GST detoxifying enzymes do 
not influence the course of CF, but that the 
ΔF508 mutation alters the age at diagnosis of 
the disease. However, epidemiological studies 
involving larger samples of patients should be 
carried out in order to clearly identify the roles 
that these mutations play in the population of 
CF patients in Brazil.
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